Cuprina Completes Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA Region, Secures Exclusive License to Market Medicinal Leeches in GCC Countries

Core Insights - Cuprina Holdings (Cayman) Limited is expanding its operations in the MENA region by establishing a laboratory in Saudi Arabia for the production of MEDIFLY maggot debridement therapy aimed at treating chronic wounds [1] - The company is also pursuing regulatory approvals necessary for selling its products in the MENA region, including a license from the Saudi Food and Drug Authority and ISO 13485 certification [2] - Cuprina MENA has secured exclusive rights to sell medicinal leeches from Biopharm UK Ltd in the GCC countries, which are increasingly utilized for various medical treatments [2][3] Company Developments - Cuprina MENA has completed the setup of a laboratory in Saudi Arabia to manufacture MEDIFLY therapy, which will enhance the company's market reach in the MENA region [1] - The company is actively working on obtaining necessary regulatory approvals to facilitate the sale of its therapies in the region [2] - The CEO of Cuprina expressed optimism about the recent milestones, indicating potential for significant incremental revenue [4] Industry Context - Medicinal leeches are gaining popularity in the GCC for treating conditions such as venous congestion and aiding in tissue healing post-surgery [3] - The use of leeches is also expanding into veterinary medicine, particularly for treating chronic blood conditions [3] - BioPharm UK Ltd is recognized as a leading provider of medicinal leeches, ensuring high clinical standards through advanced cultivation techniques [5][6]